Cascadian Therapeutics (CASC)

[tedkov]

Cascadian Shareholders Upset Over Merger Bid - (via NewsPoints Desk)
January 31, 2018
Tags: NewsPoints Cascadian Seattle Genetics United States Corporate Affairs Mergers &
Acquisitions

A group of Cascadian Therapeutics Inc. shareholders are attempting
to block the $300 million purchase of the company by Seattle Genetics.

The shareholders allege that the purchase price of $10 per share is insufficient in light of the company's growth prospects, and that deal-protection clauses in the merger agreement preclude other
companies from submitting successful competing offers. Indeed the company has over $100 million of cash on its balance sheet or $2 cash per share and no debt. In addition, shareholders allege that senior management obtained personal benefits for their own self interests in agreeing to sell the company that are not being shared with common stockholders.

Cascadian did not immediately respond to requests for a comment.
To contact the law firm on behalf of shareholders of
Cascadian for more information as to how you can participate with other shareholders for a higher price at no cost or expense call toll free 800.511.7037 or [e-mail]